SBIR/STTR Research Award

Evaluation of a therapeutic strategy to combat osteoarthritis

Award identifier bc192799ed10c28be736f5c348f5bfb8ee63a9661a7c303f46bb305981f03cd3Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$223,898

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOORG3.14 LLC
Proposal award date
2017-09-15
Contract end date
2019-05-31
UEI
F5ECMJHW2JR8
Solicitation number
PA16-302
Topic code
NIA

Research abstract

ABSTRACT Osteoarthritis OA affects over million US adults it is one of the most common chronic health conditions and a leading cause of pain and disability among adults OA is a degenerative disease of the articular joints characterized by focal areas of cartilage fibrillation articular cartilage hypertrophy bon changes and eventual destruction of the articular surface Current FDA approved treatments for OA mainly relieve pain without slow ing the progressive degeneration Other than the regular use of painkillers few therapeutic options exist Over of patients with OA are dissatisfied with their current OA therapy and a significant number eventually seek surgery There is a critical need for new therapeutic strategies to combat OA The inflammation cartilage de generation and pain associated with OA have all been proposed to be caused by a common factor the in creased synthesis of the reactive form of oxygen called superoxide radical anions SRA by polymorphonuclear leucocytes and chondrocytes in joints BG is a small molecule that reduces the synthesis of SRA Using guinea pigs with natural OA we will use BG as a tool to reduce the amount of SRA synthesized by their joint cells to levels closer to those observed in healthy animals without OA We will evaluate whether doing so prevents the symptoms of OA and the rate at which OA progresses This work will determine the extent to which reducing levels of SRA can be used as a therapeutic strategy to treat OA RELEVANCE TO PUBLIC HEALTH Osteoarthritis is a leading cause of pain and disability among adults for which there are limited treatment options This work will evaluate a potential new therapeutic strategy to combat osteoarthritis Results of this work will enable the discovery of new therapeutics for the treatment of osteoarthritis !

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2017–2019). Reported award amounts total $1,947,673. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.